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Abstract
Background: Assessment of people affected by opioid-related problems and those receiving care 
is challenging due to lack of common definitions and scattered information. We sought to fill this 
gap by demonstrating a method to describe a continuum of opioid addiction care in a large, public 
safety-net institution.
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Methods: Using 2017 clinical and administrative data from Denver Health (DH), we created 
operational definitions for opioid use disorder (OUD), opioid misuse (OM), and opioid poisoning 
(OP). Six stages along a continuum of patient engagement in opioid addiction care were 
developed, and operational definitions assigned patients to stages for a specific time point of 
analysis. National data was used to estimate the Denver population affected by OUD, OM and OP.
Results: In 2017, an estimated 6688 people aged >12 years were affected by OUD, OM, or OP 
in Denver; 48.4% (3238/6688) were medically diagnosed in DH. Of those, 32.5% (1051/3238) 
were in the medication assisted treatment stage, and, of those, 59.8% (629/1051) in the adhered to 
treatment stage. Among that latter group, 78.4% (493/629) adhered at least 90 days and 52.3% 
(329/629) for more than one year. Among patients who received medication assisted treatment, 
less than one third (31.3%, 329/1051) were adherent for more than one year.
Conclusions: A health-system level view of the continuum of opioid addiction care identified 
improvement opportunities to better monitor accuracy of diagnosis, treatment capacity, and 
effectiveness of patient engagement. Applied longitudinally at local, state and national levels, the 
model could better synergize responses to the opioid crisis.
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1. Introduction
The magnitude of the United States opioid crisis is typically monitored by counting the 
number of deaths involving prescription and illicit opioids (Ahmad et al., 2018; Scholl et al., 
2019). However, overdose deaths insufficiently represent other nonfatal effects of addiction 
or the impact of treatment.
Of nearly 20 million Americans aged >12 years who had a substance use disorder in 2016, 
an estimated 2 million people had an opioid use disorder (Ahrnsbrak et al., 2017). Untreated 
addiction and opioid overdoses may result in disability and premature death, with profound 
social consequences (American Society of Addiction Medicine, 2011a; Leshner, 1997). 
Through treatment, people living with opioid-induced illnesses can better manage their 
disease (American Society of Addiction Medicine, 2011b). Steps in addiction treatment 
among those with opioid-induced illnesses can be described as sequential stages of 
engagement in care, from screening and detection, to linkage to care, initiation of 
medication assisted treatment (MAT), and long-term adherence to care (American Society of 
Addiction Medicine, 2011b; Rinaldo and Rinaldo, 2013; Williams et al., 2017).
Near real-time estimates of the proportion of patients within each stage of engagement in 
opioid addiction care are possible with electronic health records (EHRs) and survey data. 
These assessments should help identifying people with opioid-induced problems and their 
transition from diagnosis to long-term maintenance or an opioid free life (Socias et al., 2016; 
Williams et al., 2017). Challenges exist to that assessment as terms used to describe and 
classify opioid-induced problems (e.g., misuse, abuse, poisoning, addiction, aberrant use, 
dependence, nonmedical or nontherapeutic use, physical dependence, and psychological 
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dependence) are inconsistent, overlapping, and ambiguous (Vowles et al., 2015) and 
dispersed across multiple data sources (e.g., EHRs, health insurance claims, or prescription 
drug monitoring program registries). Having standard metrics would help assess the impact 
of treatment on outcomes (Socias et al., 2016; Watkins et al., 2015).
This study sought to fill this gap by demonstrating a method to describe and visualize a 
continuum of opioid addiction care in Denver.
2. Materials and methods
2.1. Setting
Denver Health (DH) is an integrated, public safety-net institution (Gabow et al., 2003). DH 
primary care clinics employ certified addictions counselors and waivered clinicians to 
provide buprenorphine-based medication assisted treatment in the outpatient, primary care 
setting. These clinics work in a complementary and coordinated fashion with the Outpatient 
Behavioral Health Services (OBHS). OBHS, a DH substance use treatment clinic, provides 
outpatient substance and mental health treatment services. Substance treatment includes 
counseling and MAT therapies in methadone and buprenorphine-naloxone programs. 
Additionally, DH’s emergency department and waivered hospitalists can initiate 
buprenorphine therapy.
2.2. Data sources
The DH EHR provided clinical documentation, provider order entry, electronic prescribing, 
test result tracking, active medication, and problem lists. OBHS uses SAMMS™ (Chicago, 
Illinois) to register and document patient information about substance abuse treatment (e.g., 
visits, medication orders, and dosing). The two information systems were linked at the 
individual level to create a combined data set for DH patients aged ≥ 12 years in 2017.
2.3. Operational definitions and stages in the continuum of engagement in opioid 
addiction care
We constructed a continuum of engagement in opioid addiction care in DH. Stages in the 
continuum were guided by previous work (Haber et al., 2016; Socias et al., 2016; Williams 
et al., 2017, 2019) and refined through consultation with DH stakeholders. The continuum of 
opioid addiction care included stages for: estimated OUD, opioid misuse (OM), or opioid 
poisoning (OP) in Denver; diagnosed OUD, OM, or OP in DH; received MAT in DH; 
adhered to treatment; adhered to ⩾90 days of treatment; and adhered to treatment for at least 
12 months (labeled persistent adherence) (Table 1).
Definitions for each stage were constructed to allow algorithmic assignment of patients 
using an annual cohort of the linked patient records. We used International Classification of 
Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes (American Psychiatric 
Association, 2013; Centers for Disease Control and Prevention, 2013) to identify patients 
with OUD, OM, and opioid poisoning (or opioid overdose) (OP) through the DH 
organization’s patient population in 2017 (Supplementary File 2). We also looked for 
indicators of direct MAT therapy (i.e., liquid methadone administration) and buprenorphine-
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naloxone prescription refill rates at DH pharmacies in DH EHR system to generate patient 
counts for stages in the continuum of opioid addiction care. Indicators of naltrexone 
treatment were not evaluated due to poor specificity (used to treat both OUDs and alcohol 
use disorders) and limited general use (Substance Abuse and Mental Health Services 
Administration, 2018a). We excluded methadone and transdermal buprenorphine, prescribed 
for pain.
Analyses were conducted using R version 3.4.1 Microsoft Excel 2010 version. Data 
collection and analysis took place in 2018.
3. Results
The continuum of opioid addiction care in DH in 2017 can be visualized in Fig. 1. An 
estimated 6688 people aged ≥12 years in Denver had an OUD, OM or OP as defined by our 
case criteria. Among these, 3238 patients aged ≥12 years had an ICD-10-CM diagnosis code 
associated with OUD, OP, or OM for an inpatient, outpatient, or ED treatment in DH.
Approximately one third (n = 1051/3238) of DH patients with diagnosed OUD, OM or OP 
received MAT at DH. These patients attended at least one dosing visit at OBHS methadone 
or buprenorphine-naloxone programs (n = 860), received at least one buprenorphine-
naloxone prescription by a primary care prescriber at DH (n = 207), or participated in both 
contexts (n = 16).
Among those receiving MAT, 60% (n = 629/1051) adhered to prescribed treatment at DH. 
These were patients who attended at least 90% of all their daily dosing visits at the 
methadone or buprenorphine-naloxone programs of OBHS (n = 493), or patients who filled 
at least 90% of their buprenorphine-naloxone prescriptions (n = 136) in 2017.
Approximately three-quarters of patients in MAT (78.4%, n = 493/629) with ⩾90 days of 
observation after initiating MAT attended 90% or more of their daily visits at the methadone 
or buprenorphine-naloxone programs (n = 438), or filled 90% or more of their prescriptions 
(n = 55) in DH pharmacies.
Finally, two thirds (66.7%, n = 329/493) of patients who had adhered to ⩾90 days of MAT 
were in the persistent adherence stage. These patients attended 90% or more of their daily 
dosing visits in the methadone or buprenorphine-naloxone programs (n = 327), or filled 90% 
or more of their prescriptions (n = 2) in DH’s pharmacies.
4. Discussion
We defined a continuum of engagement for patients in opioid addiction care, where patients 
were assigned to specific stages based on review of 2017 data from an EHR and a treatment 
registry. This previously unavailable model allowed a public, safety-net, healthcare 
institution to visualize cross-sectional, aggregate counts of people in stages along a 
continuum of care. As DH clinicians and health system leaders reviewed this visual tool to 
assess engagement along a continuum of care, several system-wide gaps were revealed; 
areas for improvement included diagnosis, treatment, engagement, and adherence. The data 
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sources used in this study exist in many other health systems, and our methods could be used 
by both health systems and local health departments to provide timely surveillance data to 
develop engaging treatment and overdose prevention interventions.
Only 60% of patients who received MAT at DH adhered to the prescribed treatment in 2017. 
Innovative programs, such as voucher-based payments for medications for underinsured or 
uninsured patients and expanded telemedicine use, have attempted to create opportunities for 
initiating and improving adherence to MAT in other cities (Williams et al., 2017). As a 
system, DH expanded treatment capacity with extended hours of operation, enhanced points 
of access (e.g., inpatient, emergency services, and correctional care settings), and increased 
staff dedicated to treating patients with opioid addiction. Through the Center for Addiction 
Medicine established in 2019 (Mayor’s Office of City and County of Denver (2019); Denver 
Health, 2019), DH will deliver services that include prevention and education, harm 
reduction, formal treatment and management of addiction disorders, along with post-
treatment services, tools and resources that support ongoing recovery. Strategies employed 
by European countries, including simplifying transfer of stable patients from specialist 
services to continuing treatment in primary care or identifying sources of support and 
training to encourage physicians to actively provide treatment (Stover, 2011), could be 
considered in the United States.
Consistent with widespread capacity challenges across the United States (Williams et al., 
2017; Williams and Bisaga, 2016), our findings show that many of the DH patients 
diagnosed with opioid-induced problems have not received MAT. Evidence suggests that 
there are limited treatment capacity and resources at a national level. A 2012–2014 
Massachusetts study reported that only 30% of approximately 18,000 adults with a nonfatal 
drug overdose visit to an ED received MAT for opioid addiction (Larochelle et al., 2018). 
Although increasing state and federal efforts seek to reduce barriers to care, the gap between 
the number of people needing treatment and the capacity to treat them is still substantial 
(Substance Abuse and Mental Health Services Administration, 2018b).
The continuum of care model, first developed for HIV (Gardner et al., 2011), has served as a 
conceptual model to describe similar efforts (Socias et al., 2018; Williams et al., 2019, 
2018). Such continuum models provide a way to recycle information to more fully 
understand and identify opportunities for improvement. The large gap in our model, between 
diagnosis and treatment initiation, highlighted concerns with engagement strategies and 
treatment capacity. Although our approach provided a cross-sectional view from one health 
care system, a repeated measure could also be built from longitudinal data across multiple 
providers, creating a periodic jurisdictionwide assessment. The framework could help 
optimize care for OUD and design strategies to actively address gaps along the continuum of 
care.
4.1. Limitations
The estimation of the number of persons living with an opioid-induced problem in Denver 
was not the main focus of our study, but was useful to provide context to both the local 
situation and the development of our analysis. Because the estimate is based on self-reported 
data, this is likely an underestimation of the OUD, OP, and OM burdens.
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This study accessed information from within DH and might underestimate the rate of 
fulfilling prescriptions at non-DH pharmacies. However, considering many of the safety-net 
patients are unlikely to be diagnosed and have received MAT at other health care 
organizations, this is unlikely to significantly alter our results. We are working to consolidate 
healthcare data and this type of jurisdictional monitoring system across health care providers 
(Bacon et al., 2018).
5. Conclusions
A health-system level view of the continuum of opioid addiction care helped us integrate, 
summarize, and visualize information, and identify improvement opportunities to better 
monitor accuracy of diagnosis, treatment capacity, and effectiveness of patient engagement. 
Applied longitudinally at local, state and national levels, the model could better synergize 
public health, public safety and healthcare responses to the current opioid crisis.
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Fig. 1. The Continuum of Opioid Addiction Care in Denver Health in 2017.
Estimated opioid use disorder (OUD), opioid misuse (OM), or opioid poisoning (OP) in 
Denver: Calculated by applying the percentage of Coloradans aged >12 years who reported 
pain reliever use disorder or heroin use in the past year in 2015-2016 to the estimation of the 
population aged 12 or older in Denver in 2017.
Diagnosed opioid use disorder, opioid misuse, or opioid poisoning in Denver Health (DH): 
Patients >12 years with ICD-10 diagnosis codes related to opioid Use Disorder, opioid 
poisoning, or opioid misuse in the inpatient, outpatient or emergency department contexts in 
2017.
Received Medication Assisted Treatment: Patients who attended at least one dosing visit at 
DH methadone program (n=1075), OR patients who received at least one suboxone 
prescription by a primary care prescriber at DH (n=207), minus patients in both contexts 
(n=16).
Adhered to treatment: Patients who attended at least 90% of their scheduled dosing visits at 
DH methadone program (n=532), OR patients who filled at least 90% of their suboxone 
prescriptions (n=136).
Adhered to ⩾90 days of treatment: Patients with 90 days or more of scheduled dosing visits 
who attended 90% or more of their visits at DH methadone program (n=440), OR patients 
with 90 days or more of cumulated suboxone prescription days and filled 90% or more of 
their prescriptions (n=55) in DH’s pharmacies.
Persistent adherence: Patients with 365 days of scheduled daily dosing visits who attended 
90% or more of their scheduled dosing visits at DH methadone program (n=329), OR 
patients with 365 days or more of cumulated suboxone prescription days and 90% or more 
of their prescriptions (n=2) in DH’s pharmacies.
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r b
u
pr
en
or
ph
in
e-
na
lo
xo
ne
 p
ro
gr
am
s [
OR
] o
utp
ati
en
ts 
w
ho
 re
ce
iv
ed
 a
t l
ea
st 
on
e 
bu
pr
en
or
ph
in
e-
na
lo
xo
ne
 p
re
sc
rip
tio
n 
by
 a
 p
rim
ar
y 
ca
re
 p
re
sc
rib
er
 a
t D
H
.
Su
bs
ta
nc
e 
tre
at
m
en
t r
eg
ist
ry
 
an
d 
EH
R
A
dh
er
ed
 to
 tr
ea
tm
en
t
D
en
v
er
 
H
ea
lth
Pa
tie
nt
s o
n 
m
et
ha
do
ne
 th
er
ap
y 
w
er
e 
co
ns
id
er
ed
 a
dh
er
en
t i
f t
he
y 
at
te
nd
ed
 9
0%
 o
r m
or
e o
f a
ll 
th
ei
r d
ai
ly
 d
os
in
g 
vi
sit
s a
t 
th
e 
m
et
ha
do
ne
 p
ro
gr
am
. P
at
ie
nt
s w
ith
 b
u
pr
en
or
ph
in
e-
na
lo
xo
ne
 p
re
sc
rip
tio
ns
 w
er
e 
co
ns
id
er
ed
 a
dh
er
en
t i
f t
he
y 
fil
le
d 
90
%
 o
r m
or
e o
f a
ll 
th
ei
r b
u
pr
en
or
ph
in
e-
na
lo
xo
ne
 p
re
sc
rip
tio
ns
.
Su
bs
ta
nc
e 
tre
at
m
en
t r
eg
ist
ry
 
an
d 
EH
R
A
dh
er
ed
 to
 ⩾9
0 
da
ys
 o
f 
tr
ea
tm
en
t
D
en
v
er
 
H
ea
lth
Pa
tie
nt
s o
n 
m
et
ha
do
ne
 th
er
ap
y 
w
er
e 
co
ns
id
er
ed
 9
0-
da
y 
ad
he
re
nt
 if
 th
ey
 a
tte
nd
ed
 9
0%
 o
r m
or
e o
f t
he
ir 
da
ily
 d
os
in
g 
v
isi
ts 
at
 th
e 
m
et
ha
do
ne
 p
ro
gr
am
 fo
r a
t l
ea
st 
90
 d
ay
s a
fte
r t
he
ir 
in
iti
al
 ap
po
in
tm
en
t. 
Pa
tie
nt
s w
ith
 b
u
pr
en
or
ph
in
e-
n
al
ox
on
e 
pr
es
cr
ip
tio
ns
 w
er
e 
co
ns
id
er
ed
 9
0-
da
y 
ad
he
re
nt
 if
 th
ey
 h
ad
 9
0 
da
ys
 o
r m
or
e o
f c
um
ul
at
ed
 b
u
pr
en
or
ph
in
e-
n
al
ox
on
e 
pr
es
cr
ip
tio
ns
 a
nd
 fi
lle
d 
90
%
 o
r m
or
e o
f p
re
sc
rip
tio
ns
.
Su
bs
ta
nc
e 
tre
at
m
en
t r
eg
ist
ry
 
an
d 
EH
R
Pe
rs
ist
en
t a
dh
er
en
ce
 (1
 
ye
ar
)
Pa
tie
nt
s o
n 
m
et
ha
do
ne
 th
er
ap
y 
w
er
e 
co
ns
id
er
ed
 in
 p
er
sis
te
nt
 a
dh
er
en
ce
 if
 th
ey
 a
tte
nd
ed
 9
0%
 o
r m
or
e o
f t
he
ir 
da
ily
 
do
sin
g 
vi
sit
s a
t t
he
 m
et
ha
do
ne
 p
ro
gr
am
 fo
r a
t l
ea
st 
36
5 
da
ys
 af
te
r t
he
ir 
in
iti
al
 ap
po
in
tm
en
t i
n 
Ja
nu
ar
y 
20
17
. P
at
ie
nt
s 
w
ith
 b
u
pr
en
or
ph
in
e-
na
lo
xo
ne
 p
re
sc
rip
tio
ns
 w
er
e 
co
ns
id
er
ed
 3
65
-d
ay
 ad
he
re
nt
 if
 th
ey
 h
ad
 3
65
 d
ay
s o
r m
or
e o
f 
cu
m
u
la
te
d 
bu
pr
en
or
ph
in
e-
na
lo
xo
ne
 p
re
sc
rip
tio
ns
 a
nd
 fi
lle
d 
90
%
 o
r m
or
e o
f p
re
sc
rip
tio
ns
.
Su
bs
ta
nc
e 
tre
at
m
en
t r
eg
ist
ry
 
an
d 
EH
R
N
ot
e:
 
IC
D
-1
0-
CM
 =
 In
te
rn
at
io
na
l C
las
sif
ic
at
io
n 
of
 D
ise
as
es
, T
en
th
 R
ev
isi
on
, C
lin
ica
l M
od
ifi
ca
tio
n;
 
SA
M
H
SA
 =
 S
ub
sta
nc
e 
A
bu
se
 a
n
d 
M
en
ta
l H
ea
lth
 S
er
vi
ce
s A
dm
in
ist
ra
tio
n;
 S
A
M
M
S 
= 
Su
bs
ta
nc
e 
A
bu
se
 
an
d 
M
ed
ic
at
io
n 
M
an
ag
em
en
t S
ys
te
m
; E
pi
c 
= 
Ep
ic
 S
ys
te
m
s C
or
po
ra
tio
n,
 V
er
o
n
a,
 W
isc
on
sin
.
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